Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.68% | -13.18% | -18.44% | -35.24% | -38.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.94% | 32.73% | 74.70% | 86.95% | 27.24% |
| Operating Income | -25.94% | -32.73% | -74.70% | -86.95% | -27.24% |
| Income Before Tax | -10.49% | -43.87% | -85.38% | -106.31% | -40.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.49% | -43.87% | -85.38% | -106.31% | -40.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.49% | -43.87% | -85.38% | -106.31% | -40.64% |
| EBIT | -25.94% | -32.73% | -74.70% | -86.95% | -27.24% |
| EBITDA | -25.60% | -31.16% | -136.20% | -293.22% | -586.00% |
| EPS Basic | 0.58% | -40.35% | -82.05% | -103.61% | -39.55% |
| Normalized Basic EPS | -16.09% | -33.43% | -76.24% | -85.29% | -23.67% |
| EPS Diluted | 0.86% | -39.80% | -81.20% | -102.77% | -40.08% |
| Normalized Diluted EPS | -16.09% | -33.43% | -76.24% | -85.29% | -23.67% |
| Average Basic Shares Outstanding | 12.81% | 2.89% | 1.80% | 1.22% | 0.59% |
| Average Diluted Shares Outstanding | 12.81% | 2.89% | 1.80% | 1.22% | 0.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |